Aquestive Therapeutics, Inc. Overview
Pro stress-test →Aquestive is a pharmaceutical company advancing medicines through innovative science and delivery technologies, developing orally administered products to deliver complex molecules as novel alternatives to invasive and inconvenient standard therapies. The company is heavily focused on Anaphylm™, a first-in-class oral epinephrine sublingual film for treating anaphylaxis, after receiving an FDA Complete Response Letter in January 2026 with addressable deficiencies.
Strategic Profile
Pro stress-test →Aquestive operates as both a developer of proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, headquartered in New Jersey with U.S.-based manufacturing in Indiana, and is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents. The company reported approximately $120 million cash as of December 31, 2025 and plans regulatory submissions in Canada, Europe, and the UK in 2026.
Competitive Landscape
Pro stress-test →If approved, Anaphylm would be the first and only oral medication for rescue treatment of severe allergic reactions. Current competitors remain limited to epinephrine auto-injectors (EpiPen, Auvi-Q) and other conventional injection-based therapies. The company's differentiation centers on oral delivery convenience, portability, and ease of use compared to injection-based solutions.
Industry Context
Aquestive Therapeutics, Inc. operates in Pharmaceutical/Specialty Pharmaceuticals (Allergy/Emergency Medicine).
Key facts
Headquarters: Warren, New Jersey · Revenue: $44–$50M guidance 2025